Outcome After Total Knee Arthroplasty Under General or Spinal Anesthesia
Knee Osteoarthritis, Arthropathy of Knee Joint, Knee Pain Chronic
About this trial
This is an interventional treatment trial for Knee Osteoarthritis focused on measuring Total knee arthroplasty, Anesthesia, Surgical tourniquet, Pain, Postoperative nausea and vomiting, Quality of life, Length of stay, Knee function, Bioelectrical impedance, Knee endoprosthesis
Eligibility Criteria
Inclusion Criteria:
- Indication for total knee arthroplasty exists (patient has osteoarthritis, rheumatoid arthritis or other disease affecting knee joint that does not respond to conservative treatment)
- Patient understands the study information and is willing to participate
- Triathlon endoprosthesis is suitable for patient
- ASA Physical Status Classification 1-3
- Patient will be operated by a surgeon who has done at least 100 total knee arthroplasty procedures with Triathlon endoprosthesis before
Exclusion Criteria:
- BMI > 40 kg/m2
- ASA Physical Status Classification > 3
- Valgus or varus > 15° degrees in the knee that will be operated
- Extension deficit ≥ 20° or flexion ≤ 90° in the knee that will be operated
- Earlier major (open) surgery in the knee that will be operated
- Contraindication for drugs used in the study
- Contraindication for either spinal or general anesthesia
- Glomerular filtration rate < 60ml/min/1.73m2 (by Chronic Kidney DIsease Epidemiology Collaboration formula)
- Known or suspected disease affecting the function of liver
- Preoperative use of strong opioids
- Patient is pregnant, cognitively disabled, under guardianship, a prisoner or in compulsory military service
- Patient will be operated by a surgeon who has done less than 100 total knee arthroplasty procedures before or by a surgeon who does not operate with Triathlon endoprosthesis
- Day of the surgery is not suitable for study (no research personnel available for 24 hours postoperative evaluation)
Sites / Locations
- Helsinki University Central Hospital, Peijas hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Active Comparator
Active Comparator
Active Comparator
Active Comparator
Spinal anesthesia with tourniquet
Spinal anesthesia without tourniquet
General anesthesia with tourniquet
General anesthesia without tourniquet
This group will be operated under spinal anesthesia (15 mg of bupivacaine) and in continuous light propofol sedation. Surgical tourniquet (with the pressure of 250 mmHg or > 100 mmHg higher than systolic blood pressure) is used during the operation. Local infiltration analgesia (LIA) will be administered during the operation. Patients receive 1 g of intravenous tranexamic acid approximately 5 - 10 minutes before the removal of the tourniquet. Postoperatively patient-controlled analgesia (PCA) with intravenous oxycodone will be used for 24 hours.
This group will be operated under spinal anesthesia (15 mg of bupivacaine) and in continuous light propofol sedation. Surgical tourniquet is not used during the operation. Patients receive 1 g of intravenous tranexamic acid approximately 5 - 10 minutes before the surgical incision. Local infiltration analgesia (LIA) will be administered during the operation. Postoperatively patient-controlled analgesia (PCA) with intravenous oxycodone will be used for 24 hours.
This group will be operated under general anesthesia (propofol and remifentanil are used with target-controlled infusion (TCI) mode) and surgical tourniquet (with the pressure of 250 mmHg or > 100 mmHg higher than systolic blood pressure) is used during the operation. Local infiltration analgesia (LIA) will be administered during the operation. Patients receive 1 g of intravenous tranexamic acid approximately 5 - 10 minutes before the removal of tourniquet. Intravenous bolus of oxycodone 0.1 mg/kg (ideal body weight) is given when the closure of surgical wound begins. Postoperatively patient-controlled analgesia (PCA) with intravenous oxycodone will be used for 24 hours.
This group will be operated under general anesthesia (propofol and remifentanil are used with target-controlled infusion (TCI) mode) without the use of surgical tourniquet. Patients receive 1 g of intravenous tranexamic acid approximately 5 - 10 minutes before the surgical incision. Local infiltration analgesia (LIA) will be administered during the operation. Intravenous bolus of oxycodone 0.1 mg/kg (ideal body weight) is given when the closure of surgical wound begins. Postoperatively patient-controlled analgesia (PCA) with intravenous oxycodone will be used for 24 hours.